Royal Bank Of Canada Lineage Cell Therapeutics, Inc. Transaction History

Royal Bank Of Canada

$471 Billion
Q3 2024

A detailed history of Royal Bank Of Canada transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 21,692 shares of LCTX stock, worth $10,846. This represents 0.0% of its overall portfolio holdings.

Number of Shares

21,692

Previous 647,463 96.65%

Holding current value

$10,846

Previous $647,000 97.06%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$0.8 - $1.12 $500,616 - $700,863	-625,771 Reduced 96.65%	21,692 $19,000
Q2 2024 Aug 14, 2024	BUY	$0.89 - $1.47 $573,512 - $947,262	644,396 Added 21010.63%	647,463 $647,000
Q1 2024 Nov 05, 2024	SELL	$0.86 - $1.48 $554,180 - $953,706	-644,396 Reduced 99.53%	3,067 $4,000
Q1 2024 May 15, 2024	SELL	$0.86 - $1.48 $146,931 - $252,858	-170,850 Reduced 98.24%	3,067 $4,000
Q4 2023 Feb 14, 2024	BUY	$0.91 - $1.35 $143,156 - $212,375	157,315 Added 947.57%	173,917 $189,000
Q3 2023 Nov 14, 2023	BUY	$1.16 - $1.53 $2,746 - $3,623	2,368 Added 16.64%	16,602 $19,000
Q2 2023 Aug 14, 2023	BUY	$1.26 - $1.53 $16,453 - $19,978	13,058 Added 1110.37%	14,234 $20,000
Q1 2023 May 15, 2023	BUY	$1.2 - $1.53 $1,011 - $1,289	843 Added 253.15%	1,176 $1,000
Q4 2022 Feb 14, 2023	SELL	$1.02 - $1.5 $2,775 - $4,081	-2,721 Reduced 89.1%	333 $0
Q3 2022 Nov 14, 2022	SELL	$1.13 - $1.77 $2,429 - $3,805	-2,150 Reduced 41.31%	3,054 $3,000
Q2 2022 Aug 15, 2022	SELL	$1.12 - $1.61 $3,664 - $5,267	-3,272 Reduced 38.6%	5,204 $8,000
Q1 2022 May 16, 2022	SELL	$1.21 - $2.48 $24,789 - $50,807	-20,487 Reduced 70.74%	8,476 $13,000
Q4 2021 Feb 14, 2022	BUY	$1.84 - $2.68 $23,312 - $33,955	12,670 Added 77.76%	28,963 $71,000
Q3 2021 Nov 15, 2021	BUY	$2.26 - $2.86 $16,283 - $20,606	7,205 Added 79.28%	16,293 $41,000
Q2 2021 Aug 16, 2021	BUY	$2.17 - $3.0 $19,720 - $27,264	9,088 New	9,088 $26,000

Others Institutions Holding LCTX

# of Institutions

121

Shares Held

94.2M

Call Options Held

63.8K

Put Options Held

View Full List

About Lineage Cell Therapeutics, Inc.

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $84.9M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

More about LCTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.

Account

Royal Bank Of Canada Lineage Cell Therapeutics, Inc. Transaction History